Unknown

Dataset Information

0

Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.


ABSTRACT: Glioblastomas are highly aggressive adult brain tumors with poor clinical outcome. In the central nervous system (CNS) the blood-brain barrier (BBB) is the most important limiting factor for both development of new drugs and drug delivery. Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)-targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf). NPs-ZOL-Tf have been assessed on the glioblastoma cell line U373MG-LUC that showed a refractoriness in vitro to temozolomide (TMZ) and fotemustine (FTM). NPs-ZOL-Tf treatment resulted in higher in vitro cytotoxic activity than free ZOL. However, the potentiation of anti-proliferative activity of NPs-ZOL-Tf was superimposable to that one induced by NPs-ZOL (not armed with Tf). On the other hand, NPs-ZOL-Tf showed a higher antitumor efficacy if compared with that one caused by NPs-ZOL in immunosuppressed mice intramuscularly bearing U373MG-LUC xenografts, inducing a significant tumor weight inhibition (TWI). The experiments performed on mice with intracranial U373MG-LUC xenografts confirmed the efficacy of NPs-ZOL-Tf. These effects were paralleled by a higher intratumour localization of fluorescently-labeled-NPs-Tf both in intramuscular and intracranial xenografts. In conclusion, our results demonstrate that the encapsulation of ZOL increases the antitumor efficacy of this drug in glioblastoma through the acquisition of ability to cross the BBB.

SUBMITTER: Porru M 

PROVIDER: S-EPMC4279385 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.

Porru Manuela M   Zappavigna Silvia S   Salzano Giuseppina G   Luce Amalia A   Stoppacciaro Antonella A   Balestrieri Maria Luisa ML   Artuso Simona S   Lusa Sara S   De Rosa Giuseppe G   Leonetti Carlo C   Caraglia Michele M  

Oncotarget 20141101 21


Glioblastomas are highly aggressive adult brain tumors with poor clinical outcome. In the central nervous system (CNS) the blood-brain barrier (BBB) is the most important limiting factor for both development of new drugs and drug delivery. Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)-targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf). NPs-ZOL-Tf have been assessed on the glioblastoma cell line U373MG-LUC that showed a r  ...[more]

Similar Datasets

| S-EPMC4741618 | biostudies-literature
| S-EPMC3577933 | biostudies-literature
| S-EPMC4991490 | biostudies-literature
| S-EPMC8428179 | biostudies-literature
| S-EPMC5085145 | biostudies-other
| S-EPMC7698888 | biostudies-literature
| S-EPMC8254347 | biostudies-literature
| S-EPMC5522116 | biostudies-literature
| S-EPMC4452039 | biostudies-literature
| S-EPMC8781388 | biostudies-literature